scorecardresearchSyngene International Share Price Live NSE, BSE, Today - Syngene International
Mintgenie
Asian Paints3,300.706.85 (0.21%)
Axis Bank1,026.0011.90 (1.17%)
Bajaj Finance7,838.65-32.15 (-0.41%)
Bajaj Finserve1,566.15-1.80 (-0.11%)
Bharti Airtel919.607.45 (0.82%)
HCL Technologies1,261.550.95 (0.08%)
HDFC Bank1,527.20-10.45 (-0.68%)
Hindustan Unilever2,501.3021.65 (0.87%)
ICICI Bank943.15-5.40 (-0.57%)
ITC449.106.70 (1.51%)
Indusind Bank1,439.0015.50 (1.09%)
Infosys1,467.557.50 (0.51%)
Kotak Mahindra Bank1,765.252.60 (0.15%)
Larsen & Toubro2,961.7049.40 (1.70%)
Mahindra & Mahindra1,590.15-5.25 (-0.33%)
Maruti Suzuki India10,699.65150.05 (1.42%)
NTPC239.35-0.85 (-0.35%)
Nestle India22,905.95-96.75 (-0.42%)
Power Grid Corporation Of India199.350.95 (0.48%)
Reliance Industries2,369.1027.55 (1.18%)
State Bank Of India589.50-4.80 (-0.81%)
Sun Pharmaceutical Industries1,141.0016.25 (1.44%)
Tata Consultancy Services3,587.654.50 (0.13%)
Tata Motors620.400.65 (0.10%)
Tata Steel128.15-0.70 (-0.54%)
Tech Mahindra1,288.656.30 (0.49%)
Titan Company3,221.75-40.55 (-1.24%)
Ultratech Cement8,295.3569.00 (0.84%)
Wipro415.602.85 (0.69%)

Syngene International

BSE: 539268 | NSE: SYNGENE | ISIN: INE398R01022 | SECTOR: Biotechnology & Drugs

₹772.50 3.80 (0.49%)

27 Sep 2023, 09:59 (IST)

  • Open

    761.05

  • High

    774.65

  • Low

    761.05

  • Prev Close

    768.70

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    308.70B

  • Volume

    8.90K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    539268

  • NSE

    SYNGENE

  • ISIN

    INE398R01022

Syngene International Limited is an India-based integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

Company Officers

  • Jonathan Hunt

    Chief Executive Officer, Managing Director, Executive Director

  • Sibaji Biswas

    Chief Financial Officer

  • Mahesh Bhalgat

    Chief Operating Officer

  • Andrew Webster

    Chief Human Resource Officer

  • Kenneth Barr

    Senior Vice President - Discovery Services

  • Alex Del Priore

    Senior Vice President - Manufacturing Services

  • Joydeep Kant

    Senior Vice President - Development Services

  • Priyadarshini Mahapatra

    Compliance Officer, Company Secretary

  • Caroline Hempstead

    Head of Corporate Affairs

  • Alok Mehrotra

    Chief Quality Officer